MIZAJOU Ematoloji / Onkoloji 2024
Kongrè ESMO 2023
Datopotamab deruxtecan achieved the PFS endpoint for previously treated NSCLC. 177Lu PSMA-617 increases rPFS for metastatic castration resistant prostate cancer that is taxane-naive. Amivantamab combinations therapies are emerging as new options for EGFR mutated advanced NSCLC. Antibody-drug combinations improve outcomes for patients who have metastatic or inoperable breast cancer. Digital health technologies are revolutionising cancer care.
W ap itilize yon vèsyon ki pi gran nan navigatè entènèt ou a, kidonk kèk karakteristik ka pa parèt byen.
MINIMAL Kondisyon: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15-18, Apple Safari 7, SeaMonkey 2.15-2.23.
Meeting Resources19 Oct 2023OncologyPRO now offers meeting resources: +3.000 slides and webcasts; abstracts and ePosters.Access to resources.
OncologyPRO now offers meeting resources: +3.000 slides and webcasts; abstracts and ePosters.
Daily ReporterDatopotamab deruxtecan reached the PFS endpoint for previously treated NSCLC23 Oct 2023TROP2-directed ADC increased PFS and reduced toxicity in comparison with chemotherapy, but the results of TROPION Lung01 are not practice changing.
TROP2-directed ADC increased PFS and reduced toxicity in comparison with chemotherapy, but the results of TROPION Lung01 are not practice changing.
Daily Reporter177Lu PSMA-617 amelyore rPFS pou pasyan kansè pwostat ki reziste kastrasyon metastatik ki nayif 23 oktòb 2023Konklizyon esè PSMAfore a limite pa lefèt ke yo pa montre yon benefis an tèm de OS.
Enskri pou tikè oswa ti joupa
Venue Map ak otèl alantou
Minik - Holiday Inn Minik - City Centre, Bavaria, Almay Minik - Holiday Inn Minik - City Centre, Bavaria, Almay
Ban-m pran abònman